anidulafungin has been researched along with cyclosporine in 4 studies
Studies (anidulafungin) | Trials (anidulafungin) | Recent Studies (post-2010) (anidulafungin) | Studies (cyclosporine) | Trials (cyclosporine) | Recent Studies (post-2010) (cyclosporine) |
---|---|---|---|---|---|
568 | 33 | 331 | 377 | 2 | 170 |
568 | 33 | 331 | 30,547 | 3,802 | 6,558 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Byun, SY; Choi, I; Jeon, S; Kim, S; Ko, M; Lee, J; Park, S; Shum, D | 1 |
Dowell, JA; Henkel, T; Krause, D; Stogniew, M; Weston, IE | 1 |
1 review(s) available for anidulafungin and cyclosporine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for anidulafungin and cyclosporine
Article | Year |
---|---|
Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine.
Topics: Administration, Oral; Anidulafungin; Antifungal Agents; Area Under Curve; Biological Availability; Cyclosporine; Drug Administration Schedule; Drug Therapy, Combination; Echinocandins; Female; Humans; Injections, Intravenous; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Microsomes, Liver; Peptides, Cyclic; Time Factors; Tritium | 2005 |
2 other study(ies) available for anidulafungin and cyclosporine
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiops; Coronavirus Infections; COVID-19; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Niclosamide; Pandemics; Pneumonia, Viral; Pregnenediones; SARS-CoV-2; Vero Cells | 2020 |